MiMedx Group, Inc.

NASDAQ:MDXG

Biotechnology

Healthcare
$3.18 +2.22%

+$0.08 today

Market cap
$464.04M
Beta
1.46
P/E (TTM)
17.8
EPS (TTM)
$0.21
52W Low $3.03High $7.99

Volume 1.51M

Average 1.55M

MDXG Gross Margin

Gross profit as a percentage of revenue, showing how much of each sales dollar is kept after direct costs.

MiMedx Group, Inc.NASDAQ: MDXG

Gross Margin · Q1 FY2026 · quarter ended Mar 2026

Gross margin narrows to 70.6%

Gross margin was 70.6% in Q1 FY2026, down 10.7 pp from a year earlier. On a trailing-twelve-month basis it was 81.0%, down 0.8 pp year over year. Over 3 fiscal years it widened by 0.6 pp.

Context

  • Gross margin widened in 1 of the last 3 fiscal years.

Sources:Income StatementText generated from reported figures; not investment advice.

Latest quarterMar 2026
70.6%-13.3 pp QoQ
Last fiscal yearDec 2025
82.6%-0.2 pp YoY
LTMMar 2026
81.0%-0.8 pp YoY
Gross Margin past and forecast change by horizon
Horizon Past Forecast Difference
Quarter-10.7 pp——
1 year-0.2 pp——
3 years+0.6 pp——
5 years——
10 years——

Gross Margin history

Percent of revenue · from the income statement

Latest · FY2025
82.6%
Year-over-year change
-0.2pp

Gross Margin vs competitors

How MDXG compares with its peers on the latest reported figures

  • MDXG's LTM Mar 2026 gross margin of 81.0% is the 5th highest of the 8 companies compared; the peer median is 81.4%.
  • Its year-over-year change of -0.8 pp is the 6th highest of 8, against a peer median of +0.8 pp.
  • Over three fiscal years its change of +0.6 pp compares with a peer median of -0.3 pp.
MDXG Competitors Peer median
Gross Margin for MDXG and competitors
Company Period LTM level YoY 3-year change
BSEMBioStem Technologies, Inc.LTM Jun 2026112.8% +15.8 pp+6.0 pp
LCTXLineage Cell Therapeutics, Inc.LTM Mar 202698.0% +0.8 pp-0.9 pp
SMTISanara MedTech Inc.LTM Mar 202691.2% +0.8 pp+4.0 pp
RCELAVITA Medical, Inc.LTM Mar 202681.4% -4.1 pp-0.3 pp
MDXGMiMedx Group, Inc.LTM Mar 202681.0% -0.8 pp+0.6 pp
CELUCelularity Inc.LTM Dec 202576.0% +3.7 pp+85.4 pp
ORGOOrganogenesis Holdings Inc.LTM Mar 202670.4% -5.4 pp-1.1 pp
MDWDMediWound Ltd.LTM Mar 202619.6% +5.2 pp-30.5 pp
Peer median (excluding MDXG) 81.4%+0.8 pp-0.3 pp

Competitors are the stored peer set for MDXG. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.

Income Statement

USD
Metric
FY2021
Dec 2021
FY2022
Dec 2022
FY2023
Dec 2023
FY2024
Dec 2024
FY2025
Dec 2025
Revenue242.02M267.84M321.48M348.88M418.63M
Cost of Revenue39.63M48.32M54.63M60.07M73.01M
Gross Profit202.39M219.53M266.84M288.81M345.62M
Gross Margin83.6%82.0%83.0%82.8%82.6%
Research & Development9.93M12.7M12.67M12.34M15.1M
Selling, General & Admin194.85M220.85M216.3M216.39M266.19M
Operating Expenses209.44M234.25M229.73M229.94M281.29M
Depreciation & Amortization5.18M4.05M3.43M6.04M14.88M
EBITDA(1.89M)(10.69M)40.52M65.35M82.93M
EBITDA Margin-0.8%-4.0%12.6%18.7%19.8%
Operating Income(7.05M)(14.73M)37.12M58.87M63.89M
Operating Margin-2.9%-5.5%11.5%16.9%15.3%
Interest Income00004.72M
Interest Expense4.98M5.02M6.46M1.01M1.78M
Other Income / Expenses(5M)(5.02M)(6.48M)(1.57M)2.38M
Income Before Tax(12.05M)(19.75M)30.63M57.29M66.26M
Pre-Tax Margin-5.0%-7.4%9.5%16.4%15.8%
Income Tax Expense247K206K(36.81M)15.3M17.68M
Net Income(12.3M)(30.2M)67.44M42.42M48.58M
Net Margin-5.1%-11.3%21.0%12.2%11.6%
EPS (Basic)(0.09)(0.27)0.480.290.33
EPS (Diluted)(0.09)(0.27)0.380.280.32
Weighted Avg Shares110.35M112.91M116.5M146.98M147.79M
Weighted Avg Shares (Diluted)110.35M112.91M145.96M149.05M149.72M

MiMedx Group, Inc.

NASDAQ:MDXG

Intrinsic Alpha fair value

Locked

Current Price

$3.18

Margin of safety hidden

Unlock the intrinsic value to see where the current price sits on the valuation runway.

Valuation runway

Locked

Get the intrinsic value and margin of safety with a free account.